See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Zuo-Lin Xiang
Shanghai East Hospital，Tongji University School of Medicine
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Early screening and intervention therapies are crucial to improve the prognosis of hepatocellular carcinoma (HCC) patients with bone metastasis. We aimed to identify serum lncRNA as a prediction biomarker in HCC bone metastasis.
Methods
The expression levels of lnc34a in serum samples from 157 HCC patients were detected by quantitative real-time PCR. Univariate analysis and multivariate analysis were performed to determine statistically significant variables.
Results
Expression levels of lnc34a in serum from HCC patients with bone metastasis were significantly higher than those without bone metastasis. And high expression of lnc34a, vascular invasion and BCLC stage were associated with bone metastasis by analysis. Moreover, lnc34a expression was specifically associated with bone metastasis rather than lung or lymph node metastasis in HCC.
Conclusions
High serum lnc34a expression was a independent risk factor for developing bone metastasis in HCC.
Keywords
hepatocellular carcinoma, bone metastasis, serum, lnc34a
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 17 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 10 Nov, 2020
Review #5 received
Received 06 Nov, 2020
Review #4 received
Received 24 Oct, 2020
Reviewer #5 agreed
On 16 Oct, 2020
Review #3 received
Received 28 Sep, 2020
Reviewer #4 agreed
On 28 Sep, 2020
Review #2 received
Received 28 Sep, 2020
Reviewer #1 agreed
On 17 Sep, 2020
Reviewer #2 agreed
On 17 Sep, 2020
Reviewer #3 agreed
On 17 Sep, 2020
Review #1 received
Received 17 Sep, 2020
Reviewers invited
Invitations sent on 16 Sep, 2020
Editor assigned
On 04 Sep, 2020
Submission checks complete
On 03 Sep, 2020
Editor invited
On 03 Sep, 2020
First submitted
On 02 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Zuo-Lin Xiang
Shanghai East Hospital，Tongji University School of Medicine
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 17 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 10 Nov, 2020
Review #5 received
Received 06 Nov, 2020
Review #4 received
Received 24 Oct, 2020
Reviewer #5 agreed
On 16 Oct, 2020
Review #3 received
Received 28 Sep, 2020
Reviewer #4 agreed
On 28 Sep, 2020
Review #2 received
Received 28 Sep, 2020
Reviewer #1 agreed
On 17 Sep, 2020
Reviewer #2 agreed
On 17 Sep, 2020
Reviewer #3 agreed
On 17 Sep, 2020
Review #1 received
Received 17 Sep, 2020
Reviewers invited
Invitations sent on 16 Sep, 2020
Editor assigned
On 04 Sep, 2020
Submission checks complete
On 03 Sep, 2020
Editor invited
On 03 Sep, 2020
First submitted
On 02 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background
Early screening and intervention therapies are crucial to improve the prognosis of hepatocellular carcinoma (HCC) patients with bone metastasis. We aimed to identify serum lncRNA as a prediction biomarker in HCC bone metastasis.
Methods
The expression levels of lnc34a in serum samples from 157 HCC patients were detected by quantitative real-time PCR. Univariate analysis and multivariate analysis were performed to determine statistically significant variables.
Results
Expression levels of lnc34a in serum from HCC patients with bone metastasis were significantly higher than those without bone metastasis. And high expression of lnc34a, vascular invasion and BCLC stage were associated with bone metastasis by analysis. Moreover, lnc34a expression was specifically associated with bone metastasis rather than lung or lymph node metastasis in HCC.
Conclusions
High serum lnc34a expression was a independent risk factor for developing bone metastasis in HCC.
Figure 1
Loading...